---
title: "Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: References"
description: "Reference list for the formulary evidence report on Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks. 119 cited documents."
canonical: "https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: References

<a id="references"></a>

## 5 References

1. [ADARx Pharmaceuticals](https://stophae.com/)
2. [ADARx Pharmaceuticals (2023)](https://www.adarx.com/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324/)
3. [ADARx Pharmaceuticals (2025)](https://www.adarx.com/adarx-pharmaceuticals-announces-first-patient-dosed-in-phase-3-stop-hae-clinical-trial-and-orphan-drug-designation-for-adx-324-a-long-acting-sirna-in-development-for-the-prophylactic-treatment-of-her/)
4. [ADARx Pharmaceuticals Fast Track designation announcement (2026)](https://www.adarx.com/adarx-pharmaceuticals-receives-fda-fast-track-designation-for-onvuzosiran-for-the-treatment-of-hae/)
5. [ADARx Pharmaceuticals Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526458444/adrx-20260930.htm)
6. [ADARx Pharmaceuticals onvuzosiran data announcement (2026)](https://www.adarx.com/adarx-pharmaceuticals-presents-onvuzosiran-data-supporting-potential-for-sustained-attack-free-rates-with-reduced-treatment-burden-in-patients-with-hae/)
7. [ADARx Pharmaceuticals presentation (2026)](https://investors.adarx.com/static-files/fa3237f0-959a-4eec-bd69-918d384722d0)
8. [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)
9. [ADARx Pharmaceuticals third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526458321/adrx-ex99_1.htm)
10. [Argo Biopharma (2026)](https://www.prnewswire.com/news-releases/argo-biopharma-to-present-positive-phase-ii-updated-results-of-sirna-therapeutic-bw-20805-for-hae-at-bradykinin-symposium-2026-302869556.html)
11. [Arora et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37558360/)
12. [Banerji et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6583584/)
13. [Beard et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9632406/)
14. [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8)
15. [BioCryst Pharmaceuticals (2026)](https://www.sec.gov/Archives/edgar/data/882796/000117184326007097/exh_991.htm)
16. [BioCryst Pharmaceuticals Colorado WAC disclosure (2026)](https://www.biocryst.com/wp-content/uploads/Colorado-WAC-Disclosure-Orladeyo.pdf)
17. [Bork et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16490473/)
18. [Bork et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22841766/)
19. [Broderick et al. (2025)](https://link.springer.com/article/10.1186/s41687-025-00876-3)
20. [Busse et al. (2021)](https://www.haea.org/assets/img/TreatmentGuidelines040321.pdf)
21. [Busse et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41698689/)
22. [Caballero et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13327139/)
23. [Cancian et al. (2026a)](https://www.adarx.com/wp-content/uploads/2026/06/EAACI-2026_Cancian-et-al-abstract-vF.pdf)
24. [Cancian et al. (2026b)](https://www.adarx.com/wp-content/uploads/2026/06/Onvuzosiran-Provides-Deep-and-Sustained-Reduction-of-Plasma-Kallikrein-Levels-for-the-Treatment-of-HAE.pdf)
25. [Castaldo et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8133018/)
26. [Castaldo et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40414286/)
27. [Christiansen et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37619776/)
28. [ClinicalTrials.gov NCT05139810](https://clinicaltrials.gov/study/NCT05139810)
29. [ClinicalTrials.gov NCT05392114](https://clinicaltrials.gov/study/NCT05392114)
30. [ClinicalTrials.gov NCT05691361](https://clinicaltrials.gov/study/NCT05691361)
31. [ClinicalTrials.gov NCT06960213](https://clinicaltrials.gov/study/NCT06960213)
32. [ClinicalTrials.gov NCT07428499](https://clinicaltrials.gov/study/NCT07428499)
33. [CMS Clinical Laboratory Fee Schedule (2026)](https://www.cms.gov/files/zip/26clabq4.zip)
34. [CMS Medicare Part B payment limit file (2026)](https://www.cms.gov/files/zip/october-2026-medicare-part-b-payment-limit-files-final.zip)
35. [CMS Medicare Part D Spending by Drug (2026)](https://data.cms.gov/sites/default/files/2026-06/98218f98-166c-4723-8438-c344a4ef96a6/DSD_PTD_RY26_P04_V10_DY24_BGM.csv)
36. [Craig et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36868261/)
37. [Craig et al. (2026)](https://karger.com/iaa/article/doi/10.1159/000553023/953095/Prevalence-and-Incidence-of-Hereditary-Angioedema)
38. [CSL (2023)](https://newsroom.csl.com/2023-03-01-The-Lancet-Publishes-Pivotal-Phase-3-Data-on-CSLs-First-in-Class-Garadacimab-for-HAE)
39. [CSL Behring (2022)](https://labeling.cslbehring.com/PI/US/HAEGARDA/EN/HAEGARDA-Prescribing-Information.pdf)
40. [CSL Behring (2026)](https://www.haegarda.com/hcp/efficacy)
41. [Danielsson et al. (2025)](https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-europe-2025/poster-session-2-2/current-use-of-hereditary-angioedema-hae-treatments-in-sweden-an-analysis-of-the-national-prescribed-drug-register)
42. [Datta et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13685066/)
43. [Department of Veterans Affairs Federal Supply Schedule pharmaceutical prices (2026)](https://department.va.gov/procurement-acquisition-and-logistics/wp-content/uploads/sites/56/2026/11/TPharmPrices-11-01-2026.xlsx)
44. [EU Clinical Trials Register 2013-000916-10](https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000916-10/ES)
45. [Farkas et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466006/)
46. [FDA (2018)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761090s000lbl.pdf)
47. [FDA (2020)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214094s000lbl.pdf)
48. [FDA (2022)](https://www.fda.gov/media/75907/download)
49. [FDA ANDEMBRY prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761367s000lbl.pdf)
50. [FDA DAWNZERA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219407s000lbl.pdf)
51. [FDA Drug Trials Snapshot ANDEMBRY (2025)](https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-andembry)
52. [FDA Drug Trials Snapshot DAWNZERA](https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-dawnzera)
53. [FDA Drug Trials Snapshot EKTERLY](https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-ekterly)
54. [FDA ORLADEYO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214094s006lbl.pdf)
55. [FDA TAKHZYRO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761090s020lbl.pdf)
56. [Feld et al. (2026)](https://link.springer.com/article/10.1186/s41687-026-01128-8)
57. [Fisch et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39827848/)
58. [Grover et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12541594/)
59. [Guan et al. (2024)](https://link.springer.com/article/10.1186/s13023-024-03265-z)
60. [Health Research Authority (2025)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/stop-hae-a-phase-3-study-of-adx-324-in-hae/)
61. [Health Research Authority (2026)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/extension-study-of-adx-324-in-hae/)
62. [Henao et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4859422/)
63. [ICER (2021)](https://icer.org/wp-content/uploads/2020/10/ICER_Aetion_RWE_HAE_Report_082421.pdf)
64. [ICER final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_HAE_Final_Evidence_Report_111518-1.pdf)
65. [Intellia Therapeutics (2025)](https://www.sec.gov/Archives/edgar/data/0001652130/000095017025028373/ntla-ex99_1.htm)
66. [Intellia Therapeutics (2026)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-fda-acceptance-biologics-license)
67. [Intellia Therapeutics AAAAI poster (2026)](https://www.intelliatx.com/wp-content/uploads/AAAAI-2026_KKS-Modeling-Poster_with-Supplement.pdf)
68. [Intellia Therapeutics investor presentation (2024)](https://www.intelliatx.com/wp-content/uploads/Intellia_NTLA-2002-Phase-2-Data-Investor-Presentation_10.24.24_vF.pdf)
69. [Ionis Pharmaceuticals protocol and statistical analysis plan (2023)](https://cdn.clinicaltrials.gov/large-docs/10/NCT05139810/Prot_SAP_000.pdf)
70. [KalVista Pharmaceuticals Colorado WAC disclosure (2026)](https://www.kalvista.com/wp-content/uploads/2026/05/Colorado-WAC-Disclosure-Ekterly-updated-20260504.pdf)
71. [Khalid and Hitch (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12276015/)
72. [Kiani-Alikhan et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38122865/)
73. [Kim et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25280464/)
74. [Kutrieb et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13151981/)
75. [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf)
76. [Longhurst et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28328347/)
77. [Lumry et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20929608/)
78. [Lumry et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29391286/)
79. [Lumry et al. (2021)](https://onlinelibrary.wiley.com/doi/10.1111/all.14680)
80. [Lumry et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948764/)
81. [Maurer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9023902/)
82. [MedlinePlus](https://www.medlineplus.gov/genetics/condition/hereditary-angioedema/)
83. [Minafra et al. (2022a)](https://pubmed.ncbi.nlm.nih.gov/34687444/)
84. [Minafra et al. (2022b)](https://pubmed.ncbi.nlm.nih.gov/35526778/)
85. [MO HealthNet Andembry fact blast (2025)](https://mydss.mo.gov/sites/mydss/files/media/file/2025/12/6a%20-%20Andembry%20NDFB.docx)
86. [MO HealthNet Dawnzera fact blast (2025)](https://mydss.mo.gov/sites/mydss/files/media/file/2025/12/6b%20-%20Dawnzera%20NDFB.docx)
87. [Murai et al. (2026)](https://doi.org/10.1016/j.jaci.2025.12.095)
88. [NICE (2026)](https://www.nice.org.uk/guidance/GID-TA11576/documents/draft-guidance)
89. [Olson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41429313/)
90. [Pharvaris (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_1.htm)
91. [Princic et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11963383/)
92. [Riedl et al. (2024a)](https://pure.amsterdamumc.nl/en/publications/clinical-progress-in-hepatic-targeting-for-novel-prophylactic-the)
93. [Riedl et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38819395/)
94. [Riedl et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368753/)
95. [Riedl et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466153/)
96. [Riedl et al. (2026b)](https://www.annallergy.org/article/S1081-1206%2826%2900563-6/fulltext)
97. [Sandberg et al. (2024)](https://medicaljournalssweden.se/actadv/article/download/24176/46018/110086)
98. [Santé.fr (2026)](https://www.sante.fr/essais-cliniques/2025-521352-38-00/stop-hae-etude-de-phase-iii-randomisee-en-double-aveugle-et-controlee-par-placebo-evaluant-l-action-de-l-adx-324-un-sirna-ciblant-la-prekallikreine-chez-des-participants-atteints-d-angio-oedeme-hereditaire)
99. [Shah et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37395381/)
100. [Singh et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12597964/)
101. [Smith et al. (2023)](https://www.annallergy.org/article/S1081-1206%2823%2900702-0/fulltext)
102. [Staubach et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40380356/)
103. [Sundler Björkman et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8967273/)
104. [Tachdjian et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13273463/)
105. [Uminski et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12618362/)
106. [US Hereditary Angioedema Association](https://www.haea.org/)
107. [Vanya et al. (2023)](https://link.springer.com/article/10.1186/s41687-023-00576-w)
108. [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)
109. [Villa et al. (2026)](https://link.springer.com/article/10.1007/s40271-025-00798-8)
110. [Walsh et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12185836/)
111. [Watt et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10402909/)
112. [Watt et al. (2026)](https://link.springer.com/article/10.1186/s13023-025-04134-z)
113. [Weller et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27038109/)
114. [Weller et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31815297/)
115. [Wilson et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20408341/)
116. [Wong et al. (2025)](https://www.annallergy.org/article/S1081-1206%2825%2900537-X/fulltext)
117. [World Health Organization (2024)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl132.pdf)
118. [Zuraw et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33098856/)
119. [Zuraw et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40300843/)

## Related pages
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics.md)
